Press releases
- NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production
- BWXT Medical and NorthStar Medical Radioisotopes Sign Supply Agreement Supporting Actinium-225 Production
- BWX Technologies to Announce Second Quarter 2024 Results on Monday, August 5
- BWXT Awarded Phase Two of Microreactor Evaluation Contract for State of Wyoming
- BWXT-led Team Awarded $30 Billion Management and Operating Contract for National Nuclear Security Administration’s Pantex Plant
- BWXT Medical Submits Drug Master File for Actinium-225 API to U.S. Food and Drug Administration
- BWX Technologies Reports First Quarter 2024 Results
- BWXT Named First Member of GE Vernova Nuclear’s Small Modular Reactor Supplier Group
More ▼
Key statistics
As of last trade BWX Technologies Inc (4BW:DUS) traded at 93.66, -5.68% below its 52-week high of 99.30, set on Mar 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 93.30 |
---|---|
High | 93.66 |
Low | 93.30 |
Bid | 93.80 |
Offer | 95.64 |
Previous close | 92.94 |
Average volume | 28.29 |
---|---|
Shares outstanding | 91.41m |
Free float | 91.07m |
P/E (TTM) | 37.44 |
Market cap | 9.43bn USD |
EPS (TTM) | 2.76 USD |
Annual div (ADY) | 0.8834 EUR |
---|---|
Annual div yield (ADY) | 0.95% |
Div ex-date | May 16 2024 |
Div pay-date | Jun 06 2024 |
Data delayed at least 15 minutes, as of Jul 22 2024 11:31 BST.
More ▼